Drug intelligence / Profile preview

CTN-014

Development stage: Preclinical
Lead developer: Centenaire Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CTN-014 is a monoclonal antibody drug candidate developed by Centenaire Biosciences. It functions as an antagonist targeting both the epidermal growth factor receptor (EGFR) and its mutant variant EGFRvIII. The primary mechanism of action involves blocking these receptors, which are implicated in tumor growth and progression, particularly in glioblastoma and potentially other neoplasms or nervous system diseases. As of the latest update, its highest development phase is preclinical for glioblastoma[1].

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)EGFRvIII (Epidermal growth factor receptor variant III)

Beyond the preview

Go deeper on CTN-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN-014.

Explore the full profile